{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T19:31:12Z","timestamp":1777923072109,"version":"3.51.4"},"reference-count":30,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Microbial Drug Resistance"],"published-print":{"date-parts":[[2021,3,1]]},"abstract":"<jats:p>\n                    Very few antimicrobial agents remain active against\n                    <jats:italic toggle=\"yes\">Pseudomonas aeruginosa<\/jats:italic>\n                    and\n                    <jats:italic toggle=\"yes\">Klebsiella pneumoniae<\/jats:italic>\n                    in some geographic regions. We evaluated the\n                    <jats:italic toggle=\"yes\">in vitro<\/jats:italic>\n                    activity of ceftazidime\u2013avibactam, ceftolozane\u2013tazobactam, and comparator agents against 6,210\n                    <jats:italic toggle=\"yes\">P. aeruginosa<\/jats:italic>\n                    and 6,041\n                    <jats:italic toggle=\"yes\">K. pneumoniae<\/jats:italic>\n                    isolates consecutively collected from 85 U.S. medical centers across 37 states in 2016\u20132018. Antimicrobial susceptibility was determined by reference broth microdilution method.\n                    <jats:italic toggle=\"yes\">K. pneumoniae<\/jats:italic>\n                    isolates found to have elevated MICs for broad-spectrum cephalosporins were submitted to whole-genome sequencing analysis to detect resistance genes. Ceftazidime\u2013avibactam (97.1% susceptible [S]) and ceftolozane\u2013tazobactam (97.0%S) were the most active compounds against\n                    <jats:italic toggle=\"yes\">P. aeruginosa<\/jats:italic>\n                    and retained activity against meropenem-nonsusceptible (88.5\u201389.0%S), piperacillin\u2013tazobactam-nonsusceptible (86.6\u201387.0%S), and other resistant subsets of isolates. The most active agents against\n                    <jats:italic toggle=\"yes\">K. pneumoniae<\/jats:italic>\n                    per CLSI criteria were ceftazidime\u2013avibactam (&gt;99.9%S), amikacin (98.4%S), and meropenem (97.1%S). Ceftolozane\u2013tazobactam was active against 95.3% of\n                    <jats:italic toggle=\"yes\">K. pneumoniae<\/jats:italic>\n                    but showed limited activity against extended-spectrum \u03b2-lactamase and carbapenemase producers (82.9% and 0.0%S, respectively).\n                  <\/jats:p>","DOI":"10.1089\/mdr.2020.0217","type":"journal-article","created":{"date-parts":[[2020,8,7]],"date-time":"2020-08-07T13:48:16Z","timestamp":1596808096000},"page":"342-349","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":26,"title":["Antimicrobial Activity of Ceftazidime-Avibactam, Ceftolozane-Tazobactam and Comparators Tested Against\n                    <i>Pseudomonas aeruginosa<\/i>\n                    and\n                    <i>Klebsiella pneumoniae<\/i>\n                    Isolates from United States Medical Centers in 2016\u20132018"],"prefix":"10.1177","volume":"27","author":[{"given":"Helio S.","family":"Sader","sequence":"first","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cecilia G.","family":"Carvalhaes","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer M.","family":"Streit","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy B.","family":"Doyle","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariana","family":"Castanheira","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2021,3,12]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tim.2011.04.005"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01019-15"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz243"},{"key":"e_1_3_4_5_2","first-page":"1309","volume":"382","author":"Jernigan J.A.","year":"2020","unstructured":"Jernigan J.A., , Hatfield K.M, , Wolford H., , Nelson R.E, , Olubajo B., , Reddy S.C, , McCarthy N., , Paul P., , McDonald L.C, , Kallen A., , Fiore A., , Craig M., , and Baggs J.. 2020. Multidrug-resistant bacterial infections in U.S. hospitalized patients, 2012\u20132017. N. Engl. J. Med. 382:1309\u20131319.","journal-title":"Multidrug-resistant bacterial infections in U.S. hospitalized patients, 2012\u20132017. N. Engl. J. Med"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofy343"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofy347"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2016.11.001"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw243"},{"key":"e_1_3_4_10_2","unstructured":"AVYCAZ\u00ae. 2018. \u201cAVYCAZ\u00ae (ceftazidime-avibactam).\u201d Retrieved February 2018 Available at www.allergan.com\/assets\/pdf\/avycaz_pi."},{"key":"e_1_3_4_11_2","unstructured":"ZERBAXA. 2016. ZERBAXA\u00ae (ceftolozane\/tazobactam). Merck & Co. Inc. Whitehouse Station NJ."},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1089\/mdr.2018.0439"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2011.03570.x"},{"key":"e_1_3_4_14_2","unstructured":"CLSI. 2018. M07Ed11. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard. 11th edition. Clinical and Laboratory Standards Institute Wayne PA."},{"key":"e_1_3_4_15_2","unstructured":"CLSI. 2020. M100Ed30. Performance standards for antimcirobial susceptibility testing: 30th informational supplement. Clinical and Laboratory Standards Institute Wayne PA."},{"key":"e_1_3_4_16_2","unstructured":"EUCAST. 2020. Breakpoint tables for interpretation of MICs and zone diameters. Version 10.0 January 2020. Available at www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Breakpoint_tables\/v_10.0_Breakpoint_Tables.pdf (accessed January2020)."},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1089\/cmb.2012.0021"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1586\/eri.13.12"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1086\/533452"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1017\/ice.2016.174"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-0902-x"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-013-0168-2"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00875-17"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01858-17"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx424"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2019.00151"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1017\/ice.2017.197"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01045-17"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1556\/1886.2019.00001"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dku184"},{"key":"e_1_3_4_31_2","first-page":"704","article-title":"New agents for the treatment of infections with Gram-negative bacteria: restoring the miracle or false dawn? Clin","volume":"23","author":"Wright H.","year":"2017","unstructured":"Wright H., , Bonomo R.A, , and Paterson D.L.. 2017. New agents for the treatment of infections with Gram-negative bacteria: restoring the miracle or false dawn? Clin. Microbiol. Infect. 23:704\u2013712.","journal-title":"Microbiol. Infect"}],"container-title":["Microbial Drug Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/mdr.2020.0217","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/mdr.2020.0217","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/mdr.2020.0217","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T20:38:04Z","timestamp":1777667884000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/mdr.2020.0217"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,1]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3,1]]}},"alternative-id":["10.1089\/mdr.2020.0217"],"URL":"https:\/\/doi.org\/10.1089\/mdr.2020.0217","relation":{},"ISSN":["1076-6294","1931-8448"],"issn-type":[{"value":"1076-6294","type":"print"},{"value":"1931-8448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,1]]}}}